Connecting biotech, pharma, and academia to accelerate the development of longevity therapeutics.

About

As aging biology moves from theory to translation, the field faces a unique set of challenges before its promise can be realised in humans: regulatory ambiguity, lack of validated biomarkers, high-risk investment landscapes, complex clinical trial design, and scientific hype outpacing clinical data.

This forum brings together biotech leaders, pharma, investors, and translational researchers to overcome these barriers and accelerate the path from discovery to real-world intervention.

Join Longevity Leaders from biotech, pharma, academia, and VC

This two-day event will see over 30 expert speakers and over 150 delegates unite in Boston to explore the latest innovations and opportunities in longevity therapeutic development. Beginning with the fundamental science of ageing and concluding on considerations for the commercialisation of anti-ageing drugs, this meeting will cover the full spectrum of anti-ageing drug development.